Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2018

Open Access 01-12-2018 | Research

Serum proton NMR metabolomics analysis of human lung cancer following microwave ablation

Authors: Jian-Ming Hu, Huang-Tao Sun

Published in: Radiation Oncology | Issue 1/2018

Login to get access

Abstract

Background

To find potential serum biomarkers of microwave ablation (MWA) for treatment of human lung cancer by 1H nuclear magnetic resonance (NMR)-based metabolomics analysis.

Methods

Serum specimens collected from 43 healthy individuals, 39 patients with advanced non-small cell lung cancer (NSCLC) and 38 NSCLC patients treated with MWA, were subjected to 1H NMR-based metabolomics analysis. Partial least squares discriminant analysis was used to analyze the data.

Results

Compared with healthy controls, NSCLC patients showed significantly elevated serum levels of lactate, alanine, glutamate, proline, glycoprotein, phenylalanine, tyrosine and tryptophan, and markedly decreased serum levels of glucose, taurine, glutamine, glycine, phosphocreatine and threonine (p < 0.05). MWA treatment reversed the metabolic profiles of NSCLC patients towards the control group.

Conclusions

1H NMR-based metabolomics analysis enhanced the current understanding of the mechanisms involved in NSCLC, and uncovered the therapeutic potential of MWA for treatment of NSCLC. The above disturbed serum metabolites were proposed to be the potential biomarkers that may help to predict NSCLC and to evaluate the efficacy of MWA in the treatment of NSCLC.
Appendix
Available only for authorised users
Literature
1.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
2.
Wei Z, Ye X, Yang X, Huang G, Li W, Wang J, et al. Advanced non small cell lung cancer: response to microwave ablation and EGFR status. Eur Radiol. 2016:1–10.
3.
Chamarthy MR, Gupta M, Hughes TW, Velasco NB, Cynamon J, Golowa Y. Image-guided percutaneous ablation of lung malignancies: a minimally invasive alternative for nonsurgical patients or unresectable tumors. J Bronchol Interv Pulmonol. 2014;21:68–81.CrossRef
4.
Cha TS, Najihah MG, Bin Sahid I, Chuah TS. Molecular basis for resistance to ACCase-inhibiting fluazifop in Eleusine indica from Malaysia. Pestic Biochem Phys. 2014;111:7–13.CrossRef
5.
Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14:199–208.CrossRefPubMed
6.
Smith S, Jennings P. Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances. Br J Radiol. 2015;88:20140598.CrossRefPubMedPubMedCentral
7.
Zhang X, Zhu X, Wang C, Zhang H, Cai Z. Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis. Oncotarget. 2016;7:63437–48.PubMedPubMedCentral
8.
Puchades-Carrasco L, Jantus-Lewintre E, Perez-Rambla C, Garcia-Garcia F, Lucas R, Calabuig S, et al. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. Oncotarget. 2016;7:12904–16.CrossRefPubMedPubMedCentral
9.
Chen W, Lu S, Ou J, Wang G, Zu Y, Chen F, et al. Metabonomic characteristics and biomarker research of human lung cancer tissues by HR1H NMR spectroscopy. Cancer Biomark. 2016;16:653–64.CrossRefPubMed
10.
Deja S, Porebska I, Kowal A, Zabek A, Barg W, Pawelczyk K, et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014;100:369–80.CrossRefPubMed
11.
Rocha CM, Carrola J, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res. 2011;10:4314–24.CrossRefPubMed
12.
Hao D, Sarfaraz MO, Farshidfar F, Bebb DG, Lee CY, Card CM, et al. Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment. Metabolomics. 2016;12:58.CrossRefPubMedPubMedCentral
13.
Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc. 2011;6:743.
14.
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8:282–8.CrossRefPubMed
15.
Haigis MC, Deng C-X, Finley LW, Kim H-S, Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res. 2012;72:2468–72.CrossRefPubMedPubMedCentral
16.
Sebastián C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 2012;151:1185–99.CrossRefPubMedPubMedCentral
17.
Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:e301.CrossRefPubMedCentral
18.
Leevers SJ, Weinkove D, MacDougall LK, Hafen E, Waterfield MD. The drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 1996;15:6584–94.PubMedPubMedCentral
19.
Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455–64.CrossRefPubMed
20.
Hsu TY-T, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015;525:384–8.CrossRefPubMedPubMedCentral
21.
Dupuy DE. Treatment of medically inoperable non-small-cell lung cancer with stereotactic body radiation therapy versus image-guided tumor ablation: can interventional radiology compete? J Vasc Interv Radiol. 2013;24:1139–45.CrossRefPubMed
22.
Bowler K. Cellular heat injury: are membranes involved? Symp Soc Exp Biol. 1987;41:157–85.PubMed
23.
Hahn GM, Li GC, Shiu E. Interaction of amphotericin B and 43 degrees hyperthermia. Cancer Res. 1977;37:761–4.PubMed
24.
Fajardo LF, Egbert B, Marmor J, Hahn GM. Effects of hyperthermia in a malignant tumor. Cancer. 1980;45:613–23.CrossRefPubMed
25.
Robaszkiewicz A, Bartosz G, Soszynski M. N-Chloroamino acids mediate the action of hypochlorite on A549 lung cancer cells in culture. Toxicology. 2010;270:112–20.CrossRefPubMed
26.
Zhang L, Jin H, Guo X, Yang Z, Zhao L, Tang S, et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabonomic profiles. Clin Biochem. 2012;45:1064–9.CrossRefPubMed
27.
Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009;100:782–5.CrossRefPubMed
28.
Hasim A, Ali M, Mamtimin B, Ma JQ, Li QZ, Abudula A. Metabonomic signature analysis of cervical carcinoma and precancerous lesions in women by (1)H NMR spectroscopy. Exp Ther Med. 2012;3:945–51.CrossRefPubMedPubMedCentral
29.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49:1603–16.CrossRefPubMedPubMedCentral
30.
Roti Roti JL. Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperth. 2008;24:3–15.CrossRef
31.
Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E, Spraul M, et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res. 2010;9:319–32.CrossRefPubMed
32.
33.
Mondovi B, Strom R, Rotilio G, Finazzi Agro A, Cavaliere R, Rossi Fanelli A. The biochemical mechanism of selective heat sensitivity of cancer cells. I. Studies on cellular respiration. Eur J Cancer. 1969;5:129–36.CrossRefPubMed
34.
Warters RL, Roti JLR. Hyperthermia and the cell-nucleus. Radiat Res 1982;92:458–462.
35.
Menon SS, Uppal M, Randhawa S, Cheema MS, Aghdam N, Usala RL, et al. Radiation metabolomics: current status and future directions. Front Oncol. 2016;6:20.CrossRefPubMedPubMedCentral
36.
Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8:41.CrossRefPubMedPubMedCentral
37.
Jordan KW, Adkins CB, Su L, Halpern EF, Mark EJ, Christiani DC, et al. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs. Lung Cancer. 2010;68:44–50.CrossRefPubMed
38.
Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 2004;84:1014–20.CrossRefPubMed
39.
Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst. 2004;96:1805–6.CrossRefPubMed
40.
Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, et al. Lactate metabolism in human lung tumors. Cell. 2017;171:358–71. e9.CrossRefPubMed
41.
42.
Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomark Prev. 2011;20:140–7.CrossRef
43.
Kubota A, Meguid MM, Hitch DC. Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer. 1992;69:2343–8.CrossRefPubMed
Metadata
Title
Serum proton NMR metabolomics analysis of human lung cancer following microwave ablation
Authors
Jian-Ming Hu
Huang-Tao Sun
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-018-0982-5

Other articles of this Issue 1/2018

Radiation Oncology 1/2018 Go to the issue

Research

Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database

Research

Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts

Research

Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis

Review

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives

Research

Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies

Research

Children’s experiences and responses towards an intervention for psychological preparation for radiotherapy